A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Acalabrutinib
Related studies linked through entity extraction aliases.
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
- Status
- COMPLETED
- Phase
- PHASE2
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
Avo In R/R And Previously Untreated MCL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Early Intervention With Acalabrutinib in Patients With High Risk CLL
- Status
- WITHDRAWN
- Phase
- PHASE2
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments
- Status
- UNKNOWN
- Phase
- PHASE3
Study of Acalabrutinib and Tafasitamab in MZL Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2